Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.

Scheen A.

Expert Opin Drug Saf. 2013 Jul;12(4):545-57. doi: 10.1517/14740338.2013.793671. Epub 2013 Apr 27. Review.

PMID:
23621381
2.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.

Scheen AJ.

Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659. Review.

PMID:
23748503
3.

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006739. doi: 10.1002/14651858.CD006739.pub2. Review.

PMID:
18425967
4.

Tolerability of dipeptidyl peptidase-4 inhibitors: a review.

Richard KR, Shelburne JS, Kirk JK.

Clin Ther. 2011 Nov;33(11):1609-29. doi: 10.1016/j.clinthera.2011.09.028. Epub 2011 Nov 8. Review.

PMID:
22071236
5.

Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.

Scheen AJ.

Expert Opin Drug Saf. 2015 Apr;14(4):505-24. doi: 10.1517/14740338.2015.1006625. Epub 2015 Jan 29. Review.

PMID:
25630605
6.

A review of gliptins in 2011.

Scheen AJ.

Expert Opin Pharmacother. 2012 Jan;13(1):81-99. doi: 10.1517/14656566.2012.642866. Review.

PMID:
22149369
7.

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.

Scheen AJ.

Diabetes Obes Metab. 2010 Aug;12(8):648-58. doi: 10.1111/j.1463-1326.2010.01212.x. Review.

PMID:
20590741
8.

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.

Monami M, Dicembrini I, Mannucci E.

Diabetes Obes Metab. 2014 Jan;16(1):48-56. doi: 10.1111/dom.12176. Epub 2013 Jul 28.

PMID:
23837679
9.

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.

Monami M, Dicembrini I, Martelli D, Mannucci E.

Curr Med Res Opin. 2011 Nov;27 Suppl 3:57-64. doi: 10.1185/03007995.2011.602964.

PMID:
22106978
10.

Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?

Clifton P.

Clin Ther. 2014 Dec 1;36(12):2072-9. doi: 10.1016/j.clinthera.2014.10.009. Epub 2014 Nov 13. Review.

PMID:
25453730
11.

Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.

Balakumar P, Dhanaraj SA.

Cell Signal. 2013 Sep;25(9):1799-803. doi: 10.1016/j.cellsig.2013.05.009. Epub 2013 May 22. Review.

PMID:
23707531
12.
13.

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.

Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, Rios LP, Malaga G, Wong E, Sohani Z, Guyatt GH, Sun X.

BMJ. 2014 Apr 15;348:g2366. doi: 10.1136/bmj.g2366. Review.

14.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Review.

PMID:
23263796
15.

Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.

Monami M, Dicembrini I, Mannucci E.

Nutr Metab Cardiovasc Dis. 2014 Jul;24(7):689-97. doi: 10.1016/j.numecd.2014.01.017. Epub 2014 Mar 5.

PMID:
24793580
16.

DPP-4 inhibitors: focus on safety.

Tella SH, Rendell MS.

Expert Opin Drug Saf. 2015 Jan;14(1):127-40. doi: 10.1517/14740338.2015.977863. Epub 2014 Dec 9. Review.

PMID:
25488788
17.

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Mikhail N.

Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845 . Review.

PMID:
18491986
18.

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

Scheen AJ.

Diabetes Metab. 2012 Apr;38(2):89-101. doi: 10.1016/j.diabet.2011.11.001. Epub 2011 Dec 22. Review.

19.

Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes.

Mikhail N.

Curr Drug Saf. 2011 Nov 1;6(5):304-9. Review.

PMID:
22424537
20.

Alogliptin for the treatment of type 2 diabetes.

White JR.

Drugs Today (Barc). 2011 Feb;47(2):99-107. doi: 10.1358/dot.2011.47.2.1583163. Review.

PMID:
21431099

Supplemental Content

Support Center